Abstract: A low residue antiperspirant and/or deodorant composition in the form of an anhydrous, surfactant-free and antiseptic alcohol-free suspension exhibiting a syneresis of less than 8% is disclosed which comprises: (a) a dimethicone/vinyldimethicone crosspolymer composition made by reacting a polymethylhydrogensiloxane with an alpha, omega-divinylpolydimethyl siloxane for which the dimethicone/vinyldimethicone crosspolymer composition is used at a concentration of 0.5–10% in cyclomethicone; (b) polyethylene beads having a density in the range of 0.91–0.98 grams/cm3 and a particle size in the range of 5–40 microns, wherein the polyethylene beads are used in an amount of at least 2% by weight based on the total weight of the composition; (c) a volatile silicone; (d) an emollient or mixture of two or more emollients; and (e) an effective amount of an antiperspirant active material.

Abstract: A dosage formulation for once daily administration prior to sleeping is described that provides an initial delay in pharmaceutical release followed by controlled release of the pharmaceutical. There is also provided a method for preparing a time specific delayed, controlled release formulation of dosage, which method includes coating a single pellet with at least one dosage layer, which is coated by at least one seal coat and at least one outer rate controlling layer of a water soluble polymer coat. The dosage formulation of this invention provides a substantially drug free interval of about 0 to 5 hours followed by a drug delivery interval at a rate permitting bioavailability thereof for up to about 24 hours following oral administration. A method of using the formulations of the present invention for the treatment of early morning pathologies, including atrial fibrillation, is also described.

Abstract: A method of treating or preventing restenosis by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient.

Abstract: This invention provides a sterol-modified silicone compound which is low melting, hydrophilic and very suitable for emulsifying, represented by the general formula R1aR2bSiO(4?a?b)/2, and having a melting point of 40° C. or less, and provides a cosmetic material containing this silicone compound having excellent stability and moisture retention properties R1 in the general formula is a monofunctional alkyl group, aryl group, aralkyl group or fluorine-substituted alkyl group having 1–10 identical or different carbon atoms, which does not contain an aliphatic unsaturated bond, and R2 is an organic group represented by the general formula —(CpH2pO(CqH2qO)r—X, where X is a monofunctional residue excepting the hydroxyl group of sterol, a and b are integers satisfying the relations 1.0?a?2.5, 0.001?b?1.0, and 1.5?a+b?2.6, respectively, p is an integer in the range 2–6, q is an integer in the range 2–4, and r is an integer in the range 3–200.

Abstract: A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm3. In addition to the medicament, the particles can include other materials such as, for example, phospholipids, amino acids, combinations thereof and others.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

Abstract: A pharmaceutical formulation in the form of a dry powder which comprises amoxycillin and clavulanate in a weight ratio of from 2:1 to about 16:1 and a pharmaceutically acceptable carrier or excipient and flavouring agents which provide a straw-berry flavour, further modified by the addition of extra components to add a creamy flavour or an extra fruity flavour.

Abstract: The present invention provides emollient creams composed of sulfur, sodium sulfacetamide and a botanically-derived anti-inflammatory ingredient. The creams are alcohol-free and have a pH at or above 7.0.

Abstract: Herein is disclosed a cosmetic composition comprising, as active ingredients, one or more members selected from the group consisting of mono-N?-acylarginines and cosmetic powders whose surfaces have been treated with a mono-N?-acylarginine (Ingredient A) and one or more members selected from the group consisting of water-soluble polymers and alcohol-soluble polymers (Ingredient B), which cosmetic composition is excellent in conditioning effects such as moist feeling and voluminous feeling in the case of hair cosmetics and excellent in feelings upon use such as smoothening property and moist feeling without sticky feeling and occlusive feeling in the case of skin cosmetics.

Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

Abstract: A method of administering a medication to a post operative patient with the medication being administered at the site of a surgery performed on the patient. The medication is formed into a time release capsule (10) having a core (12) of the medication which is dispensed within the body over a predetermined period of time. The capsule is covered with a coating (14) that dissolves within the body. The time release medication is not released until the covering is sufficiently dissolved to expose the medication. During surgery, the surgeon places placing a plurality of capsules (10–10n) in the patient's body at the surgery site. The respective capsules have different coating thicknesses so the medication contained therein is dispensed at different periods of time after the surgery as a function of the thickness of the coating.

Abstract: The present invention relates to optimized formulations of antiinflammatory steroids for nebulisation and a process for the preparation thereof. More particularly, the invention relates to formulations for monodose or multidose vials in the form of preservative-free stable solutions of a more acceptable osmolarity, which can effectively be nebulised with the nebulisers currently available on the market and are well-tolerated by patients.

Abstract: Decorative cosmetic preparations that contain water-soluble ?-(1,3) glucans, which have intact ?-(1,3) side-chains and are free from repetitive ?-(1,6) linkages and a method of producing the same are disclosed.

Abstract: Formulations for the administration through pressurized metered dose aerosol inhalers containing an anticholineric drug in solution in a hydrofluorocarbon propellant, a cosolvent and a low volatility component, and the use thereof in chronic obstructive pulmonary disease.

Abstract: An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.

Abstract: Cosmetic or dermatological composition characterized in that it comprises a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent.

Abstract: The invention provides methods and materials for evaluating cardiovascular conditions (e.g., angina conditions). Specifically, the invention provides methods and materials related to determining whether or not a mammal has at least one unstable plaque. The invention also provides kits for assessing cardiovascular conditions, substantially pure populations of cells, and methods of identifying compounds to treat life-threatening cardiovascular conditions (e.g., unstable angina).

Abstract: An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual. The vehicle is particularly well-suited to delivery of insulin from immunoisolated islets of Langerhans, and can also be used advantageously for delivery of high molecular weight products, such as products larger than IgG. A method of making a biocompatible, immunoisolatory implantable vehicle, consisting in a first embodiment of a coextrusion process, and in a second embodiment of a stepwise process.

Abstract: An improvement in a method of treating benign gynecological disorders is described. In the method, treatment of a benign gynecological disorder with a composition comprised of a gonadotropin releasing hormone (GnRH) compound and an estrogenic compound, and optionally, an androgenic compound, is extended to premenopausal women who are not receiving an exogenously supplied progestin on a regular or periodic basis. Treatment in accord with the invention does not increase significantly the risk of endometrial hyperplasia. The method is also suitable for contraception.